Compare TG Therapeutics Inc (TGTX) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Consumer Staples Select Sector SPDR Fund trades at $83.97. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| TGTX | XLP | |
|---|---|---|
Market Cap | $8.26B | — |
Sector | Health | — |
52-Week High | $59.06 | $90.00 |
52-Week Low | $26.39 | $75.61 |
Enterprise Value | $8.50B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLP trades at $84.86, down 0.39% with a bullish technical signal from moving averages. The ETF shows strong analyst support with a 100% buy rating from 2 analysts and a 2.6% dividend yield. Recent news highlights XLP's defensive positioning amid market volatility, with consumer staples gaining favor as investors seek stability.
The outlook remains positive given XLP's defensive sector exposure and strong technical momentum. Key risks include sector concentration and macroeconomic pressures on consumer spending. With unanimous analyst bullishness and technical indicators supporting further upside, XLP presents a stable equity opportunity in uncertain markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
